date:Jul 21, 2012
rate Alzheimers Disease (AD), Axona has been on the US market since 2009, he said.
More than 30,000 people have used it since the launch and it is now covered by more than 1,350 health plans in the US.
Asked about the science behind the product, which is claimed to improve memory and cognitive function in mild to moderate AD patients, he said: Accera has already done four human clinical trials on people with memory impairment and mild to moderate AD to demonstrate its safety and efficacy.
But